article thumbnail

10 Game-Changing Transformations Reshaping the Global Molecular Biomarkers Industry by 2030

Frost & Sullivan

The landscape of global molecular biomarkers is rapidly evolving, driven by advancements in biotechnology and the increasing demand for personalized medicine. Molecular biomarkers serve as critical indicators for disease presence, progression, and response to treatment, particularly in oncology and other therapeutic areas.